Group 1 - The core message is the inclusion of the HPV vaccine in China's national immunization program, which is expected to significantly reduce cervical cancer cases among young women in the country [1][2][5] - The announcement was made unexpectedly during a press conference on September 11, 2023, catching many stakeholders by surprise despite prior rumors [2][3] - The decision is seen as a culmination of nearly two decades of advocacy and research efforts by experts in the field, particularly highlighting the contributions of key figures like Qiao Youlin [3][4][5] Group 2 - The HPV vaccine's journey to approval in China has been lengthy, with the first vaccine being approved globally in 2006 and entering China in 2014, leading to a nearly 20-year wait for its inclusion in the national program [5][6][12] - The initial high cost of the vaccine, approximately $360 (around 4300 RMB today), posed significant barriers to access, particularly for lower-income populations [6][12] - The vaccine distribution faced bureaucratic hurdles, with a significant delay caused by regulatory approvals, which resulted in donated vaccines being redirected to other countries [6][8][9] Group 3 - Clinical trials for the HPV vaccine in China faced challenges, requiring extensive local data to satisfy regulatory requirements, which prolonged the approval process [10][11][12] - The approval of the 9-valent HPV vaccine in 2018 marked a significant milestone, with the process taking only eight days compared to previous lengthy approvals, indicating a shift in regulatory efficiency [13][15] - The global health community, including the WHO, emphasizes the importance of equitable access to the HPV vaccine, particularly for vulnerable populations, to effectively combat cervical cancer [16][17]

Group 1 - The core point of the article is the inclusion of the HPV vaccine in the national immunization program starting from November 10, 2025, providing free vaccinations for girls born after November 10, 2011, who are 13 years old or older [1] - The initiative aims to maximize prevention effectiveness and reduce the incidence and mortality rates of cervical cancer, based on WHO recommendations and China's national conditions [1] - The Chinese Center for Disease Control and Prevention (CDC) will be responsible for aggregating vaccine demand and conducting centralized procurement, with a budget of 425 million yuan [1] Group 2 - The HPV vaccine to be provided is the bivalent type, with a recommended two-dose schedule spaced six months apart [1] - The suppliers for the vaccine will be Wantai Biological Pharmacy and Watson Biotech, which is expected to enhance vaccination rates and promote health equity [1]